Dr. Tripathy on Treatment De-Escalation in HER2+ Breast Cancer
In Partnership With:
Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.
Debu Tripathy, MD, professor of medicine and chair of the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, discusses treatment de-escalation in HER2-positive breast cancer.
Patients with clinical stage I HER2-positive breast cancer may be eligible for de-escalated dosing of weekly paclitaxel and trastuzumab (Herceptin), says Tripathy.
Prior to de-escalation, patients will typically undergo up-front surgery to confirm that their disease is not being upstaged, says Tripathy.
If the patient has confirmed early-stage disease, or their tumor is under 3 cm, therapy de-escalation can be considered per data from the phase 2 APT trial, explains Tripathy.
The field is currently awaiting the randomized data from the phase 2 ATEMPT trial to determine whether ado-trastuzumab emtansine (T-DM1; Kadcyla) could be de-escalated, Tripathy concludes.
